Business · 14/04/1994Updated: 10/15/2026 · 1 min read
Prospective Grant of Exclusive License: Treatment of Dopaminergic Neurodegenerative Disorders
Summary
The National Institutes of Health (NIH) is contemplating granting an exclusive worldwide license to Phoenix: Regenerative Technologies, Inc. for a novel surgical implantation method to treat dopaminergic neurodegenerative disorders, pending no objections within 60 days.